Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming ...

Concentra Biosciences offers $3/share + CVR for Acelyrin, outperforming Alumis' bid. Read why I rate SLRN stock a Sell at ...

It’s a possibility, as most things are at Marvel Studios, but fans probably shouldn’t count on it. At least that’s the verbal ...

Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

President Donald Trump's envoy to the Middle East, Steve Witkoff, said Sunday that he would aim to negotiate an "extension" of Phase One of the Israel-Hamas hostage release and ceasefire deal when ...

Hamas declared on Saturday its readiness to move to the second phase of the ceasefire agreement in Gaza, reiterating that the completion of prisoner-hostage exchanges depends on Israel’s full ...

“When I got to the phase of my life where I was traveling pretty constantly … you can pretty much always know that a scotch and soda is going to be refreshing and pretty decent,” John sai ...

Hades 2 launched into Early Access in mid-2024, though there's still no word when a v1.0 update will see it launch to all platforms. The latest major update, however, marks an important moment in ...

Some eight years since the Nintendo Switch was released, we have finally got an official look at the Nintendo Switch 2. In a rather brief trailer, Nintendo showed off its next-generation gaming ...

Prime Minister Benjamin Netanyahu told cabinet ministers during a recent meeting that Israel’s conditions in upcoming negotiations on the terms of the second phase of the ceasefire and hostage ...

Marvel Phase 5 has almost come to an end. Indeed, its final three projects are due to land in theaters and on Disney Plus by late June, so there's no time like the present to find out what we know ...